Markets

Merit Medical: Strong Buy on New Approvals, Pipeline Strength

On Dec 23, Zacks Investment Research raised Merit Medical Systems, Inc.MMSI to a Zacks Rank #1 (Strong Buy) on new regulatory approvals and an encouraging product pipeline.

Why the Upgrade?

Merit Medical recently announced the receipt of regulatory approvals for four new products.

Merit Medical's Centros Dialysis Catheter has gained CE Marking, upon which the company now markets the product in European territories. It is to be noted that the device has been available in the U.S. for quite some time. Merit Medical also received CE Marking for HepaSphere Microspheres with Irinotecan indication, which is expected to complement the doxorubicin indication.

In the U.S., Merit Medical received FDA approval for the Elation Wireguided Balloon Dilation Catheter with biliary indication, which is touted to complement the company's esophageal indication. Additionally, the company's Prelude SNAP Splittable Hydrophilic Sheath gained approval from the FDA and is expected to complement its existing uncoated sheath.

The four new approvals are expected to considerably strengthen the company's product portfolio. We believe, upon successful launch of these products, the company will be able to achieve greater market penetration, which will in turn drive top-line growth. Merit Medical also boasts an encouraging product pipeline, which includes safety centesis catheter, the PAL Planner and the 40 atm basixTOUCH Inflation Syringe.

Estimate Revision

The Zacks Consensus Estimate for fiscal 2016 has remained steady at 86 cents over the past 30 days, reflecting a year-over-year increase of 9.9%. Similarly, the Zacks Consensus Estimate for fiscal 2017 stand at 97 cents, reflecting year-over-year growth of 12.5%.

Other Stocks to Consider

Other favorably ranked stocks include Masimo MASI , Steris Plc STE and Abiomed ABMD . While Masimo and Steris sport a Zacks Rank #1 (Strong Buy), Abiomed has a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ABIOMED INC (ABMD): Free Stock Analysis Report

MASIMO CORP (MASI): Free Stock Analysis Report

MERIT MEDICAL (MMSI): Free Stock Analysis Report

STERIS PLC (STE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABMD MMSI MASI STE

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More